849093-96-5

Upstream product

• 6959-47-3 2-chloromethylpyridine hydrochloride 
• 1160850-37-2 methyl N-(tert-butoxycarbonyl)-S-(pyridin-2-ylmethyl)-L-cysteinate 
• 849093-95-4 S-(pyridin-2-ylmethyl)-Boc-L-cysteine 
• 890040-38-7 (R)-2-amino-3-(pyridin-2-ylmethyl-sulfanyl)-propionic acid methyl ester hydrochloride 
• 655-32-3 2,2,2-trifluoro-1-(4-fluorophenyl)ethanone 

Relevant academic research and scientific papers

SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds of formula ( I ) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is-alkylene-SO2NR5R6.

SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.